理聘网-单位详情页，四川大学生物治疗国家重点实验室

基本介绍  State/National Key Laboratory of Biotherapy (SKLB) was established by the Ministry of Sciences and Technology in China in 2005, and became one of the National Research and Development (R&D) Platforms for Novel Drugs founded by the Ministries of Sciences and Technology as well as Public Health in September 2008. It is also supported by National Collaborative Innovation Program and became the National Collaborative Innovation Center for Biotherapy in April 2013. The Platform is located in the High Tech Zone of Chengdu and the Medical Campus of Sichuan University. The overall space is nearly 70,000 square meters and is still under intensive growth and construction. SKLB also has rich clinical resources of West China Hospital, which has 4,300 beds. 学科建设    SKLB is becoming a highly-regarded, comprehensive and multidisciplinary research center in China. Through the seamless integration of basic research, preclinical development, translational and clinical medicine, an efficient and fully integrated technology chain for the discovery and development of innovative drug candidates has been established in a single institute. Part of the mission of this Platform is to improve the treatment of major human diseases such as cancer, cardiovascular diseases, obesity, diabetes mellitus, infectious diseases (hepatitis, AIDS, and tuberculosis etc), inflammatory diseases, neurological disease, as well as chronic autoimmune diseases. Focusing on more than 200 important targets, hundreds of projects for basic research and  biologic drugs (such as gene and cell therapy, vaccines, and monoclonal antibodies, recombinant proteins, etc), synthetic small molecule drugs and small molecule natural products are ongoing. 科研平台 生物治疗国家重点实验室主要研究领域和方向为人类疾病生物治疗研究的若干重大基础理论和生物技术药物开发等，形成了以分子生物学、肿瘤学、免疫学、基因组学、蛋白质科学、化学生物学等为理论基础的多学科综合、交叉、融合的六个技术平台和研究领域。     1. 重大疾病生物治疗研究技术平台，重点研究针对肿瘤、感染性疾病 （如肝炎、HIV、等）、心血管疾病、自身免疫疾病、呼吸系统疾病、遗传病等的生物治疗.     2．重大疾病生物治疗的基础研究技术平台，重点发展和完善基因组学、蛋白组学和生物信息学的研究平台，建立模式生物、基因敲除平台，重点进行重要致病基因的克隆、鉴定及突变分析与基因多态性的研究；免疫应答分子机理研究；信号传导与细胞凋亡研究等，为人类重大疾病生物治疗奠定理论基础及提供新的靶分子。     3．生物技术药物（包括重组蛋白、多肽、单克隆抗体及基因治疗药物等）研究与开发技术平台，重点建设哺乳动物细胞发酵平台、抗体研究与开发平台和靶向免疫基因治疗技术平台，以及建立规范化创新生物技术药物质量评价体系。     4．纳米生物技术平台，重点研究靶向式药物释放（微纳米）载体（膜）技术、可控降解药物胶囊材料与系统、研究靶向药物与新型给 药系统。     5．干细胞基础与应用研究平台，重点研究人胚胎干细胞、骨髓基质干细  胞、造血干细胞、肌肉干细胞和脂肪干细胞等。     6．组织工程与移植免疫研究平台，重点研究工程化组织替代（包括骨、 软骨、肌腱、皮肤、角膜）、消化及泌尿管道的再生与修复（主要采用工程化组织替代及诱导组织再生技术，重点是食管、膀胱、尿道、 胆道）；心脏病的治疗（包括心肌缺血的再生，组织工程人工心瓣，异位节律的重建，冠心病的补片材料）。 科研成果 近5年来，实验室共承担了国家重点基础研究发展规划“973”专项（首席科学家所在单位）和子课题、国家高技术研究发展计划“863”重点或重大专项、科技部基础研究重大项目前期研究专项、国家自然科学基金创新研究群体基金、国家杰出青年科学基金以及国家自然科学基金重点项目等在内的国家级重大课题60余项，国家自然科学基金面上项目和省部级科研项目100余项。